Claims for Patent: 10,028,503

Summary for Patent: 10,028,503

Title:	Platelet storage methods and compositions for same
Abstract:	Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.
Inventor(s):	Zheng; Yi (Cincinnati, OH), Cancelas; Jose (Cincinnati, OH)
Assignee:	CHILDREN\'S HOSPITAL MEDICAL CENTER (Cincinnati, OH)
Application Number:	14/743,213
Patent Claims:	1. A composition for cold platelet storage at 0 to 20.degree. C. comprising platelets; a RHOA inhibitor selected from: ##STR00008## or pharmaceutically acceptable salt thereof, ##STR00009## or pharmaceutically acceptable salt thereof, or combinations thereof; and a physiologically acceptable carrier, wherein said R-G04, S-G04, or combination thereof, is present in an amount of at least about 10.mu.M. 2. The composition according to claim 1, wherein said carrier comprises a buffer. 3. The composition according to claim 1, wherein said carrier is selected from saline, phosphate buffered saline, Tris buffered saline, Hank's buffered saline, water, or a combination thereof. 4. The composition according to claim 1, wherein said carrier comprises an electrolyte solution. 5. The composition according to claim 1, wherein said composition comprises an additive selected from NaCl, KCl, CaCl2, MgCl2, MgSO4, Na3 citrate, citric acid, NaHCO3, Na phosphate, Na acetate, Na gluconate, glucose, maltose, mannitol, and combinations thereof. 6. The composition according to claim 1, wherein said composition comprises an additive selected from NaCl, KCl, CaCl2, MgCl2, MgSO4, Na3 citrate, citric acid, NaHCO3, Na phosphate, Na acetate, Na gluconate, glucose, maltose, mannitol, and combinations thereof, wherein said additive is present in an amount of from about 0.5mmol/L to about 150 mmol/L. 7. The composition according to claim 1, wherein said composition comprises one or more additives selected from D-ribose, D-glucose, Hanks solution, Hepes solution, bovine serum albumin, tic anticoagulant peptide and sterile water, or combinations thereof. 8. The composition according to claim 1 comprising an additive selected from a pH adjusting agent, a pH buffering agent, a tonicity adjusting agent, a stabilizer, a wetting agent, and combinations thereof. 9. The composition according to claim 1, wherein said composition has a pH of from about 5 to about 8. 10. The composition according to claim 1, wherein said composition is isotonic. 11. The composition according to claim 1, wherein said composition comprises an additional therapeutic agent. 12. A method for storing platelets comprising storing said platelets in a composition according to claim 1. 13. The method of claim 12, wherein said RHOA inhibitor is present at a concentration of from about 10 .mu.M to about 500 .mu.M. 14. The method of claim 12, wherein storing is carried out at a temperature of from about 1.degree. C. to about 20.degree. C. 15. The method of claim 12, wherein storing is carried out for a period of time of from about 7 to 20 days. 16. The method of claim 12 wherein said composition is used in an amount sufficient to inhibit a platelet damaging activity selected from polymerization of F-actin, depolymerization of F-actin, actomyosin contraction, tubulin polymerization, and spectrin anchorage. 17. The method of claim 12 wherein platelet survival is greater than about 65% after a storage period of 24 hours at 5.degree. C. 18. The method of claim 12 wherein said storing step is carried out at a temperature of about 0.degree. C. 19. A method of reversing platelet activation comprising contacting activated platelets with the composition of claim 1. 20. A method of reversing refrigeration storage lesion in platelets comprising contacting platelets having refrigeration storage lesions with the composition of claim 1. 21. The composition of claim 1, wherein said RHOA inhibitor is present in an amount of from about 10 .mu.M to about 500 .mu.M. 22. The composition of claim 1, wherein said RHOA inhibitor is present in an amount of from about 25 .mu.M to about 300 .mu.M. 23. The composition of claim 1, wherein said RHOA inhibitor is present in an amount of from about 50 .mu.M to about 200 .mu.M. 24. The composition of claim 1, wherein said RHOA inhibitor is present in an amount of from about 75 .mu.M to about 150 .mu.M. 25. The composition of claim 1, wherein said RHOA inhibitor is R-G04. 26. The composition of claim 1, wherein said RHOA inhibitor is S-G04.

Details for Patent 10,028,503

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2034-06-18